NCT05984602 2026-03-30A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic CancerNYU Langone HealthPhase 1 Active not recruiting9 enrolled